I am a
Home I AM A Search Login

Papers of the Week

2020 Jun 17

Am J Clin Dermatol

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.


Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M, Hide M, Sher L, Hussain I, Chen Z, Khokhar FA, Beazley B, Ruddy M, Patel N, Graham NMH, Ardeleanu M, Shumel B
Am J Clin Dermatol. 2020 Jun 17.
PMID: 32557382.


Management of moderate-to-severe atopic dermatitis (AD) commonly requires long-term treatment.